Northland Capital Markets Starts Aytu Biosciences (AYTU) at Outperform
- Wall Street ends volatile week sharply higher
- AT&T (T) in Talks to Merge Media Assets with Discovery (DISCA) - WSJ
- Disney (DIS) Dips As Streaming Business Shows Signs of Slowing Down, Analysts 'Very Bullish' on LT Opportunity
- Airbnb (ABNB) Bookings Up 52% to Help Sales Beat, Seen as a 'Blow Out Quarter' as More Upside is Left
- DoorDash (DASH) Reports Bigger Loss and a Sales Beat, Shares Soars on Strong Guidance and Two Upgrades to 'Buy'
News and research before you hear about it on CNBC and others. Claim your 1-week free trial to StreetInsider Premium here.
Northland Capital Markets initiates coverage on Aytu Biosciences (NASDAQ: AYTU) with a Outperform rating and a price target of $10.00.
Shares of Aytu Biosciences closed at $1.45 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Aytu BioScience (AYTU) BioPharma Announces Publication of In Vitro Study Demonstrating That Ultraviolet-A Light Increases Mitochondrial Anti-Viral Signaling Protein
- UPDATE: Goldman Sachs Starts Altair Engineering (ALTR) at Buy
- Citi Reinstates General Electric (GE) Coverage with 'Buy' and a 'Street-High' Price Target Amid Improving Execution
Create E-mail Alert Related CategoriesHot New Coverage, New Coverage
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!